Dec 15 2010
Amira Pharmaceuticals, Inc. announced today that it will present preclinical and clinical data from its DP2 receptor antagonist program on December 17, 2010, at Pacifichem 2010 in Honolulu, Hawaii. The data from Amira's clinical-stage DP2 program will be delivered by Brian Stearns, Ph.D., in a presentation titled "Discovery and optimization of a novel series of DP2 antagonists with efficacy in mouse models of COPD and asthma."
"We are very excited about the two structurally distinct clinical stage molecules, AM211 and AM461," said Peppi Prasit, Ph.D., Chief Scientific Officer. "In particular, the safety and pharmacodynamic readouts displayed by these compounds allowed us to investigate doses that ranged all the way to complete inhibition of the receptor at trough plasma concentrations."
The DP2 receptor is part of the Arachidonic Acid pathway and is also known as CRTH2, or chemoattractant receptor-homologous molecule expressed in Th2 lymphocytes. DP2 is a high affinity receptor for the prostaglandin D2 and in humans is implicated in Th2-dependent allergic inflammation.
SOURCE Amira Pharmaceuticals, Inc.
Spermidine regulates RIPK1 to combat diabetes and vascular damage